/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

C

Craig L. Leonardi

Central Dermatology(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

179

Papers

21.3K

Citations

57

h-index

116

i10-index

Craig L. Leonardi is an academic researcher from Central Dermatology. The author has contributed to research in topics: Psoriasis: Treatment and Pathogenesis & Dermatology and Skin Diseases & Pharmaceutical studies and practices. The author has an h-index of 57, co-authored 153 publications.

Research Topics

Psoriasis: Treatment and Pathogenesis Dermatology and Skin Diseases Pharmaceutical studies and practices Health Systems, Economic Evaluations, Quality of Life Autoimmune Bullous Skin Diseases

Papers by this author

works

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

2008 · The Lancet · 1,852 citations

https://doi.org/10.1016/s0140-6736(08)60725-4

Craig L. Leonardi Alexa B. Kimball Kim Papp Newman Yeilding

Clinical Goals and Barriers to Effective Psoriasis Care

2018 · Dermatology and Therapy · 91 citations

https://doi.org/10.1007/s13555-018-0279-5

Bruce Strober Joelle M. van der Walt April W. Armstrong Marc Bourcier

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis

2011 · Journal of the American Academy of Dermatology · 82 citations

https://doi.org/10.1016/j.jaad.2011.07.040

David M. Pariser Craig L. Leonardi Kenneth B. Gordon Alice B. Gottlieb

Basal cell carcinoma of the scrotum

1992 · Journal of the American Academy of Dermatology · 66 citations

https://doi.org/10.1016/0190-9622(92)70083-r

George T. Nahass Andrew Blauvelt Craig L. Leonardi Neal S. Penneys

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

2020 · Dermatology and Therapy · 57 citations

https://doi.org/10.1007/s13555-020-00367-x

Craig L. Leonardi Kristian Reich Peter Foley Hideshi Torii

Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis

2022 · Dermatology and Therapy · 56 citations

https://doi.org/10.1007/s13555-022-00760-8

April W. Armstrong Kyle Fahrbach Craig L. Leonardi Matthias Augustin

Research topics

topics

Psoriasis: Treatment and Pathogenesis

Dermatology and Skin Diseases

Pharmaceutical studies and practices

Health Systems, Economic Evaluations, Quality of Life

Autoimmune Bullous Skin Diseases

Chat about Author

Papers

Chat

Click to start Chat